|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"chung hc"
Showing items 1-25 of 34 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
| 國家衛生研究院 |
2025-04-29 |
Identifying rare germline variants associated with metastatic prostate cancer through an extreme phenotype study
|
Lin, YY;Noghabi, HS;Volik, S;Bell, R;Sar, F;Haegert, A;Chung, HC;Fazli, L;Oo, HZ;Daugaard, M;Kuo, MH;Hsu, SC;Imeda, EL;Zanettini, C;Queiroz, L;Schlotmann, B;Gheybi, K;Cooper, C;Kote-Jarai, Z;Eeles, R;Kung, HJ;Marchionni, L;Weischenfeldt, J;Miller, KD;Rabinowitz, A;Wang, Y;Zhang, HF;Sorensen, PH;Carey, MS;Gleave, M;Hayes, VM;Gibson, WT;Collins, CC |
| 國家衛生研究院 |
2022-02 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-contr
|
Kang, YK;Chen, LT;Ryu, MH;Oh, DY;Oh, SC;Chung, HC;Lee, KW;Omori, T;Shitara, K;Sakuramoto, S;Chung, IJ;Yamaguchi, K;Kato, K;Sym, SJ;Kadowaki, S;Tsuji, K;Chen, JS;Bai, LY;Oh, SY;Choda, Y;Yasui, H;Takeuchi, K;Hirashima, Y;Hagihara, S;Boku, N |
| 國家衛生研究院 |
2021-09-04 |
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post hoc subanalysis from the ATTRACTION-2 study
|
Kang, YK;Morita, S;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Sameshima, H;Chen, LT;Boku, N |
| 國家衛生研究院 |
2021-03-20 |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku, N;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Nishiyama, T;Chen, LT;Kang, YK |
| 國家衛生研究院 |
2020-09 |
Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
|
Boku, N;Ryu, MH;Oh, DY;Oh, SC;Chung, HC;Lee, KW;Omori, T;Shitara, K;Sakuramoto, S;Chung, IJ;Yamaguchi, K;Kato, K;Sym, SJ;Kadowaki, S;Tsuji, K;Chen, JS;Bai, LY;Chen, LT;Kang, YK |
| 國家衛生研究院 |
2020-02 |
A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data
|
Chen, LT;Kang, YK;Satoh, T;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, W;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Boku, N |
| 國家衛生研究院 |
2019-12-20 |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen, LT;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Sameshima, H;Kang, YK;Boku, N |
| 國家衛生研究院 |
2019-02 |
Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2
|
Kang, YK;Satoh, T;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Morita, S;Chen, LT;Boku, N |
| 國家衛生研究院 |
2018-12-19 |
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase 2 trial (AT
|
Boku, N;Ryu, MH;Kato, K;Chung, HC;Minashi, K;Lee, KW;Cho, H;Kang, WK;Komatsu, Y;Tsuda, M;Yamaguchi, K;Hara, H;Fumita, S;Azuma, M;Chen, LT;Kang, YK |
| 國家衛生研究院 |
2018-09 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials
|
Haag, GM;Chen, LT;Kang, YK;Satoh, T;Kato, K;Chung, HC;Kang, WK;Chao, Y;Chen, JS;Ott, PA;Le, DT;Zhao, H;Exposito, MJJ;Janjigian, YY;Boku, N;Chau, I |
| 國家衛生研究院 |
2018-05 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials
|
Chau, I;Chen, LT;Kang, YK;Satoh, T;Kato, K;Chung, HC;Kang, WK;Chao, Y;Chen, JS;Ott, PA;Le, DT;Zhao, HY;Jimenez-Exposito, MJ;Janjigian, YY;Boku, N |
| 國家衛生研究院 |
2018-02 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials
|
Chau, I;Chen, LT;Kang, YK;Satoh, T;Kato, K;Chung, HC;Kang, WK;Chao, Y;Chen, JS;Ott, PA;Le, DT;Zhao, H;Jimenez-Exposito, MJ;Janjigian, YY;Boku, N |
| 國家衛生研究院 |
2017-12 |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial
|
Kang, YK;Boku, N;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Chen, LT |
| 國家衛生研究院 |
2017-09 |
ATTRACTION-05 (ONO-4538-38/BMS CA209844): A randomized, multicenter, double-blind, placebo-controlled Phase 3 study of Nivolumab (Nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction (G/EGJ) cancer
|
Terashima, M;Kim, YW;Yeh, TS;Chung, HC;Chen, JS;Boku, N;Kang, YK;Chen, LT;Sasako, M |
| 國家衛生研究院 |
2017-09 |
Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37)
|
Kang, YK;Kato, K;Chung, HC;Minashi, K;Lee, KW;Cho, H;Kang, WK;Komatsu, Y;Tsuda, M;Yamaguchi, K;Hara, H;Fumita, S;Azuma, M;Boku, N;Chen, LT |
| 國家衛生研究院 |
2017-09 |
A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)
|
Boku, N;Kang, YK;Satoh, T;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Chen, LT |
| 國家衛生研究院 |
2017-02 |
Healthy lifestyle and normal waist circumference are associated with a lower 5-year risk of type 2 diabetes in middle-aged and elderly individuals: Results from the healthy aging longitudinal study in Taiwan (HALST)
|
Chen, CC;Liu, K;Hsu, CC;Chang, HY;Chung, HC;Liu, JS;Liu, YH;Tsai, TL;Liaw, WJ;Lin, IC;Wu, HW;Juan, CC;Chiu, HC;Lee, MM;Hsiung, CA |
| 國家衛生研究院 |
2017-02 |
Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial
|
Kang, YK;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Boku, N;Chen, LT |
| 國立交通大學 |
2014-12-08T15:19:22Z |
Formation of pyramid-like nanostructures during cobalt film growth by magnetron sputtering
|
Liu, CP; Chang, JJ; Chen, SW; Chung, HC; Wang, YL |
| 臺北醫學大學 |
2014 |
Methionine oxidation in albumin by fine haze particulate matter: An in vitro and in vivo study
|
Lee, KY;CKC, Wong;Chung, KJ;Bien, MY;Cao, JJ;Han, YM;Tian, L;Chang, CC;Feng, PH;Ho, KF;Chung, HC |
| 國家衛生研究院 |
2012-12 |
A Cullin3-KLHL20 ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression
|
Lee, YR;Yuan, WC;Huang, SF;Lin, YM;Chen, TY;Chung, HC;Tsai, CH;Chen, HY;Chiang, CT;Lai, CK;Lu, LT;Chen, CH;Gu, DL;Pu, YS;Jou, YS;Lu, K;Hsiao, PW;Shih, HM;Chen, RH |
| 國家衛生研究院 |
2011-08 |
A Cullin3-KLHL20 ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression
|
Yuan, WC;Lee, YR;Huang, SF;Lin, YM;Chen, TY;Chung, HC;Tsai, CH;Chen, HY;Chiang, CT;Lai, CK;Lu, LT;Chen, CH;Gu, DL;Pu, YS;Jou, YS;Lu, KP;Hsiao, PW;Shih, HM;Chen, RH |
| 國家衛生研究院 |
2010-05 |
Risk factors of isolated antibody against core antigen of hepatitis B virus: association with HIV infection and age but not hepatitis C virus infection
|
Liang, SH;Chen, TJ;Lee, SS;Tseng, FC;Huang, CK;Lai, CH;Chiou, CP;Wang, JL;Chung, HC;Lin, JN;Kuo, YC;Lin, HH |
| 義守大學 |
2009-08 |
Epidemiology of Acute Q Fever, Scrub Typhus, and Murine Typhus, and Identification of Their Clinical Characteristics Compared to Patients with Acute Febrile Illness in Southern Taiwan
|
Lai CH; Huang CK; Chen YH;Chang LL;Weng HC;Lin JN;Chung HC;Liang SH;Lin HH |
| 義守大學 |
2009-05 |
The difference in clinical characteristics between acute Q fever and scrub typhus in southern Taiwan
|
Lai CH; Huang CK; Weng HC;Chung HC;Liang SH;Lin JN;Lin CW;Hsu CY;Lin HH |
Showing items 1-25 of 34 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
|
